|Bid||0.00 x 1888800|
|Ask||0.00 x 10722300|
|Day's Range||0.23 - 0.24|
|52 Week Range||0.14 - 0.70|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.13|
MELBOURNE, Australia, Jan. 10, 2018-- Immuron Limited is pleased to advise investors that CEO Dr Jerry Kanellos, was interviewed on The RedChip Money Report US television program. The interview will air ...
MELBOURNE, Australia, Dec. 06, 2017-- Immuron Limited wishes to advise investors that CEO Dr Jerry Kanellos is scheduled to present at RedChip’ s Global Online Growth Conference on Wednesday, December ...
MELBOURNE, Australia, Nov. 22, 2017-- Immuron Limited wishes to advise investors that Van Leeuwenhoeck Institute, a prominent European and US-based Life Sciences Research and Analyst firm, has published ...
MELBOURNE, Australia, Nov. 15, 2017-- Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated ...
MELBOURNE, Australia, Nov. 09, 2017-- Immuron Limited, an Australian microbiome biopharmaceutical company focused on developing and commercialising oral immunotherapeutics for the treatment of gut-mediated ...
Significant growth of sales for Immuron’ s over-the-counter supplement Travelan ® for Q1 2018 compared to Q1 2017 Travelan ® US experienced a 197% increase in sales compared to Q1 2017 Travelan ® Australia ...
U.S. exchanges are set to record their busiest year for IPOs from Asian firms since 2010 and may sustain the pace in 2018, as startups from Taiwan, Singapore, Indonesia and Vietnam join a flurry of Chinese firms that have already listed in the country. Chinese issuers have dominated U.S. IPO activity for several years, but Nasdaq and rival New York Stock Exchange (NYSE) have been increasingly targeting firms from fast-growing Southeast Asian economies and startups from Japan and Australia to counter their dependence on mainland companies.